Baltimore, Maryland – March 11, 2024 Auxergen announces its latest product: an in-vitro assay to measure the pharmacokinetics of THC, CBD and like cannabinoids, which promises to revolutionize the field of cannabis research and diagnostics, with application to drug discovery, design, efficacy testing, and a host of therapeutic uses. The Auxergen cannabinoid biokinetics (CBK) assay…
Baltimore, Maryland – March 11, 2024 Auxergen, Inc. has achieved Qualified Maryland Biotechnology Company (QMBC) status for 2024. QMBC status provides early-stage biotechnology companies with refundable tax credits to help offset high research and development costs. Auxergen develops phage-based cures for agricultural, environmental, and human diseases. The company is currently fielding a bio-control solution to combat the…
At Auxergen, we are thrilled to share a promising update on our XylePhage project, a revolutionary endeavor aiming to safeguard a 95% of the world’s olive oil production currently threatened by the perilous Olive Quick Decline Syndrome (OQDS).